MEDIKURA

Project "MEDIKURA" data sheet

The following table provides information about the project.

 Partnership

Take a look of project's partnership.

Map

 Project objective

The mission of MEDIKURA is to digitize drug safety: our process innovation helps pharma companies to capture, enrich, and analyze drug-related data provided by patients and doctors. We address the societal problem that more than 200,000 European citizens die from Adverse Drug Reactions (ADRs, colloquially referred to as drug side-effects) every year, whereas less than 1% of ADR cases are officially reported by patients and doctors. To improve drug safety, the new EU regulation ICH E2B(R3) came into effect in late 2017 - as a result, pharma companies are subject to increasing cost and time pressure in ADR monitoring.

Our solution is to build the digital infrastructure for ADR data – to improve drug safety, enable more targeted therapies, and accelerate data-driven drug discovery. We streamline the process of capturing, enriching, and analyzing ADR data through a cloud-based platform that connects pharma companies with patients and doctors. Our goal is to replace the decentralized, analogue drug safety process with a transparent, centralized, and digital system. The resulting value proposition to pharma companies is three-fold. In terms of time savings, we reduce the timespan to close a ADR case and report it to public authorities by more than 50%. In terms of money, we can save processing cost of more than 50% per ADR case and reduce liability risk significantly. In terms of data quality, we provide comprehensive information through a digital backchannel to both patients and doctors that allows to enrich drug-related data and prepare it for subsequent analyses.